Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "before instituting treatment with ceftriaxone appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug therapy may be instituted prior to obtaining results of susceptibility testing to reduce the development of drug resistant bacteria and maintain the effectiveness of ceftriaxone for injection usp and other antibacterial drugs ceftriaxone for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy ceftriaxone for injection usp is indicated for the treatment of the following infections when caused by susceptible organisms lower respiratory tract infections caused by streptococcus pneumoniae staphylococcus aureus haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae escherichia coli enterobacter aerogenes proteus mirabilis serratia marcescens acute bacterial otitis media caused by streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis note in one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection usp compared to 1 days of oral therapy in a second study comparable cure rates were observed between single dose ceftriaxone for injection usp and the comparator the potentially lower clinical cure rate of ceftriaxone for injection usp should be balanced against the potential advantages of parenteral therapy see clinical studies skin and skin structure infections caused by staphylococcus aureus staphylococcus epidermidis streptococcus pyogenes escherichia coli enterobacter cloacae klebsiella oxytoca klebsiella pneumoniae proteus mirabilis morganella morganii pseudomonas aeruginosa serratia marcescens acinetobacter calcoaceticus bacteroides fragilis peptostreptococcus urinary tract infections complicated and uncomplicated caused by escherichia coli proteus mirabilis proteus vulgaris morganella morganii klebsiella pneumoniae uncomplicated gonorrhea cervical urethral and rectal caused by neisseria gonorrhoeae neisseria gonorrhoeae pelvic inflammatory disease caused by neisseria gonorrhoeae chlamydia trachomatis chlamydia trachomatis bacterial septicemia caused by staphylococcus aureus streptococcus pneumoniae escherichia coli haemophilus influenzae klebsiella pneumoniae bone and joint infections caused by staphylococcus aureus streptococcus pneumoniae escherichia coli proteus mirabilis klebsiella pneumoniae enterobacter intra abdominal infections caused by escherichia coli klebsiella pneumoniae bacteroides fragilis clostridium clostridium difficile peptostreptococcus meningitis caused by haemophilus influenzae neisseria meningitidis streptococcus pneumoniae staphylococcus epidermidis escherichia coli efficacy for this organism in this organ system was studied in fewer than ten infections surgical prophylaxis the preoperative administration of a single 1 g dose of ceftriaxone for injection usp may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated e g vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high risk patients such as those over 7 years of age with acute cholecystitis not requiring therapeutic antimicrobials obstructive jaundice or common duct bile stones and in surgical patients for whom infection at the operative site would present serious risk e g during coronary artery bypass surgery although ceftriaxone for injection usp has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery no placebo controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery when administered prior to surgical procedures for which it is indicated a single 1 g dose of ceftriaxone for injection usp provides protection from most infections due to susceptible organisms throughout the course of the procedure" ?g. }

• association label "before instituting treatment with ceftriaxone appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug therapy may be instituted prior to obtaining results of susceptibility testing to reduce the development of drug resistant bacteria and maintain the effectiveness of ceftriaxone for injection usp and other antibacterial drugs ceftriaxone for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy ceftriaxone for injection usp is indicated for the treatment of the following infections when caused by susceptible organisms lower respiratory tract infections caused by streptococcus pneumoniae staphylococcus aureus haemophilus influenzae haemophilus parainfluenzae klebsiella pneumoniae escherichia coli enterobacter aerogenes proteus mirabilis serratia marcescens acute bacterial otitis media caused by streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis note in one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection usp compared to 1 days of oral therapy in a second study comparable cure rates were observed between single dose ceftriaxone for injection usp and the comparator the potentially lower clinical cure rate of ceftriaxone for injection usp should be balanced against the potential advantages of parenteral therapy see clinical studies skin and skin structure infections caused by staphylococcus aureus staphylococcus epidermidis streptococcus pyogenes escherichia coli enterobacter cloacae klebsiella oxytoca klebsiella pneumoniae proteus mirabilis morganella morganii pseudomonas aeruginosa serratia marcescens acinetobacter calcoaceticus bacteroides fragilis peptostreptococcus urinary tract infections complicated and uncomplicated caused by escherichia coli proteus mirabilis proteus vulgaris morganella morganii klebsiella pneumoniae uncomplicated gonorrhea cervical urethral and rectal caused by neisseria gonorrhoeae neisseria gonorrhoeae pelvic inflammatory disease caused by neisseria gonorrhoeae chlamydia trachomatis chlamydia trachomatis bacterial septicemia caused by staphylococcus aureus streptococcus pneumoniae escherichia coli haemophilus influenzae klebsiella pneumoniae bone and joint infections caused by staphylococcus aureus streptococcus pneumoniae escherichia coli proteus mirabilis klebsiella pneumoniae enterobacter intra abdominal infections caused by escherichia coli klebsiella pneumoniae bacteroides fragilis clostridium clostridium difficile peptostreptococcus meningitis caused by haemophilus influenzae neisseria meningitidis streptococcus pneumoniae staphylococcus epidermidis escherichia coli efficacy for this organism in this organ system was studied in fewer than ten infections surgical prophylaxis the preoperative administration of a single 1 g dose of ceftriaxone for injection usp may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated e g vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high risk patients such as those over 7 years of age with acute cholecystitis not requiring therapeutic antimicrobials obstructive jaundice or common duct bile stones and in surgical patients for whom infection at the operative site would present serious risk e g during coronary artery bypass surgery although ceftriaxone for injection usp has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery no placebo controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery when administered prior to surgical procedures for which it is indicated a single 1 g dose of ceftriaxone for injection usp provides protection from most infections due to susceptible organisms throughout the course of the procedure" assertion.